SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp AI-infrastructure and neocloud selloff, as traders weigh concerns about heavy buildout spending, financing and whether future returns will justify it; Gartners warning about consolidation in the sector has added to the concern. After a rebound, the community is split between buyers calling the decline oversold and a chance to accumulate, and skeptics who see a temporary bounce with more downside risk.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling overwhelmingly bearish discussion, with traders linking the weakness to Trumps declining approval and midterm-election risk, as well as skepticism about the companys business fundamentals and Truth Social engagement. Some users argue the stock is driven more by political sentiment than operating performance, while a smaller bullish contingent sees potential for a rebound.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and rising Treasury yields have intensified fears of tighter Fed policy, weighing on rate-sensitive small caps and pushing the Russell 2000 into correction territory. Traders are divided between expecting an oversold bounce near support and warning that the breakdown below key technical levels could extend the decline.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs upcoming third-quarter earnings report is the main focus, with traders weighing expectations for another strong quarter against uncertainty around costs. Discussion also centers on NHTSAs review of the L87 V8 recall remedy after reports of post-repair engine failures, and whether the issue could add warranty or legal exposure.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

CEO Scott Kirbys support for steep wealth and inheritance taxes has drawn sharp criticism and boycott calls, with some traders arguing his political comments could hurt the airline. Attention is also focused on upcoming earnings, with debate over resilient demand and bullish expectations versus fuel costs and economic uncertainty.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rises on concerns that Middle East shipping disruptions and attacks on energy infrastructure could constrain supply, alongside strikes on Russian oil facilities. Traders are split between expecting further gains from a persistent supply-risk premium and betting that diplomacy or easing tensions could unwind the rally.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention after a prolonged selloff and fresh lows, with traders debating whether high valuation, dilution and weak price action outweigh its defense-growth prospects. Bulls point to contract momentum and demand for drones and hypersonics as reasons the pullback may be an opportunity, while bears remain focused on the stocks continued decline.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas Q3 earnings miss and reduced full-year outlook, driven by sharply higher fuel costs, are the main focus despite resilient travel demand and premium revenue. Traders are split between seeing strong bookings and fare pricing as supportive and worrying that fuel and other expenses will keep squeezing margins.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after a steep selloff to post-IPO lows, with traders citing staged lockup expirations and insider share sales as added selling pressure alongside a TD Cowen price-target cut. The bearish debate centers on OpenAI customer concentration and the companys ability to scale, while bulls point to its AI-chip technology and argue the shares are oversold.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff alongside AI and data-center peers is widely blamed on its convertible-note financing and expected dilution, compounded by concerns about managements execution and weak sector sentiment. Most discussion is frustrated and bearish over repeated lows, while some traders maintain the long-term AI infrastructure thesis and see potential for an oversold rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns 

Equity

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 


ABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Data

Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.


ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears  

Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial. 


ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment

The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment. 


Goldman Sachs ETF Trust - Goldman Sachs Hedge IND VIP ETF

Neutral Sentiment

<ul class="summary-bullets"><li>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating.</li><li>Wedbush said that it remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning.</li><li>Abivax also announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares.</li></ul><p>Shares of Abivax (ABVX) clocked their best day in about 11 months on Tuesday on the heels of multiple price target revisions and updated safety and efficacy data from a study that addressed prior investor worries about cancer risk tied to its ulcerative colitis candidate, obefazimod.</p><p>ABVX stock closed 39% higher and slipped marginally by 0.15% after-hours, at the time of writing, after the company announced a $600-million public offering.</p><h2 class="st-heading-2">Trial Data</h2><p>Abivax <a href="https://stocktwits.com/news-articles/markets/equity/abvx-stock-rockets-after-abivax-eases-drug-safety-concerns-with-fresh-clinical-data/cZ19pPuR7L8">released</a> the updated study data after-hours on Monday. The data showed malignancy rates, including non-melanoma skin cancers, remained consistent with background rates in ulcerative colitis patients. Four NMSC cases were reported in Part 2 of the trial—two per dose arm—mostly in patients with pre-existing risk factors, while two additional non-NMSC malignancies in the 50 mg group were deemed unrelated to the drug.</p><p>Abivax said the data reinforce obefazimod’s favorable benefit-risk profile. More than one-third of patients in the higher-dose group achieved clinical remission and mucosal healing at week 44. The company plans to submit a U.S. FDA new drug application in the fourth quarter.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating. The analyst said the latest update provided additional safety data confirming a sufficiently clean safety profile for obefazimod. BTIG’s new price target represents a potential upside of about 31% from the stock’s closing price on Tuesday.</p><p>Wedbush analyst David Nierengarten raised the firm’s price target to $110 from $90 but kept a Neutral rating. While the pooled safety data appeared in line with background malignancy rates in ulcerative colitis, Wedbush remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning. Nierengarten’s new price target assumed a potential downside of about 17% from the stock’s closing price.</p><p>Jefferies upgraded Abivax to Buy from Hold and lifted its price target to $158 from $108, representing a potential upside of nearly 19% from the stock’s last close. The firm said the Part 2 update “appropriately addresses the key overhang facing the stock” and that management did a good job addressing investor concerns with the presentation of the safety data. Jefferies also noted that the efficacy profile continues to strengthen with additional data.</p><h2 class="st-heading-2">Abivax Launches $600-Million Public Offering</h2><p>Separately, Abivax announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares. The company intends to use the net proceeds for U.S. commercialization expenses of obefazimod, clinical development in ulcerative colitis and Crohn’s disease, and general corporate purposes.</p><h2 class="st-heading-2">How Did ABVX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ABVX stayed within the ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user opined that the capital raise is to convince interested partners that the company can also move forward solo.</p><p><stembedurl>https://www.stocktwits.com/Miles223/message/657970692</stembedurl></p><p>Another user echoed the sentiment, positioning the capital raise as proof that the company received “lowball M&amp;A offers.”</p><p><stembedurl>https://www.stocktwits.com/p3akyblinder/message/657971234</stembedurl></p><p>A third user voiced hopes for an imminent near-term buyout for the company.</p><p><stembedurl>https://www.stocktwits.com/MZ2X/message/657969299</stembedurl></p><p><a href="https://stocktwits.com/symbol/ABVX">ABVX stock</a> has traded nearly flat year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uncy-stock-clocks-worst-day-in-year-analysts-keep-buy-ratings-despite-5-12-month-delay-in-drug-approval/cZ1QMSoR70o">UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 

Abivax - ADR

iShares Biotechnology ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

GVIP Goldman Sachs ETF Trust - Goldman Sachs Hedge IND VIP ETF

Fundamentals

Latest GVIP News